Imunon Inc (IMNN)

Currency in USD
3.1800
-0.1400(-4.22%)
Closed·
3.1900+0.0100(+0.31%)
·
IMNN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.15503.3600
52 wk Range
2.990041.2174
Key Statistics
Prev. Close
3.32
Open
3.33
Day's Range
3.155-3.36
52 wk Range
2.99-41.2174
Volume
47.2K
Average Volume (3m)
54.87K
1-Year Change
-72.452%
Book Value / Share
1.62
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMNN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.3333
Upside
+665.20%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Imunon Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Imunon Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Imunon Inc Earnings Call Summary for Q3/2025

  • Imunon reduced Q3 net loss to $3.4M from $4.8M YoY, with operating expenses down 31% and R&D costs dropping 44%, despite stock volatility post-earnings
  • Cash position stands at $5.3M as of September 30, 2025, with runway projected to extend until mid-Q1 2026 as the company manages expenses
  • OVATION 3 trial enrollment continues with completion targeted by late 2028, though executives emphasized urgency to accelerate with additional funding
  • Minimal Residual Disease study enrollment expected to reach cap by H1 2026, potentially enabling BLA filing and full product approval following successful analyses
  • Stock closed regular trading up 7.09% at $3.95 before declining 2.23% in premarket, reflecting mixed investor sentiment about clinical progress and funding needs
Last Updated: 13/11/2025, 17:18
Read Full Transcript

Compare IMNN to Peers and Sector

Metrics to compare
IMNN
Peers
Sector
Relationship
P/E Ratio
−0.8x−2.2x−0.6x
PEG Ratio
−0.010.070.00
Price/Book
2.6x4.2x2.6x
Price / LTM Sales
-63.4x3.4x
Upside (Analyst Target)
387.8%363.5%44.9%
Fair Value Upside
Unlock9.6%6.3%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 24.3333
(+665.20% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Brookline Capital Markets
Buy16.00+403.14%21.00Maintain07/01/2026
H.C. Wainwright
Buy14.00+340.25%-Maintain20/06/2025
H.C. Wainwright
Buy14.00+340.25%12.00Maintain28/02/2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-1.16 / -0.21
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Imunon (IMNN) Income Statement & Profits

People Also Watch

0.336
ITRM
+9.28%
1.550
AMTX
+1.31%
0.9800
COCP
-0.02%
1.4700
POLA
-5.77%
1.180
KXIN
-1.67%

FAQ

What Is the Imunon (IMNN) Share Price Today?

The live Imunon share price today is 3.1800

What Stock Exchange Does Imunon (IMNN) Trade On?

Imunon is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Imunon?

The stock symbol (also called a 'ticker') for Imunon is "IMNN."

What Is the Current Imunon Market Cap?

As of today, Imunon market capitalisation is 10.98M.

What Is Imunon's (IMNN) Earnings Per Share (TTM)?

The Imunon EPS is currently -9.54 (Trailing Twelve Months).

When Is the Next Imunon Earnings Date?

Imunon's next earnings report will be released on 13 Nov 2025.

Is IMNN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Imunon moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Imunon Stock Split?

Imunon has split 5 times. (See the IMNN stock split history page for full effective split date and price information.)

How Many Employees Does Imunon Have?

Imunon has 25 employees.

What is the current trading status of Imunon (IMNN)?

As of 03 Feb 2026, Imunon (IMNN) is trading at a price of 3.1800, with a previous close of 3.3200. The stock has fluctuated within a day range of 3.1550 to 3.3600, while its 52-week range spans from 2.9900 to 41.2174.

What Is Imunon (IMNN) Price Target According to Analysts?

The average 12-month price target for Imunon is USD24.3333, with a high estimate of USD45 and a low estimate of USD12. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +665.20% Upside potential.

What Is the IMNN Premarket Price?

IMNN's last pre-market stock price is 3.3400. The pre-market share volume is 150.0000, and the stock has decreased by 0.0200, or 0.6000%.

What Is the IMNN After Hours Price?

IMNN's last after hours stock price is 3.1900, the stock has decreased by 0.0100, or 0.3100%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.